The Methodist Hospital Research Institute

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

115

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

14 drugs in development

Phase 31

Phase 29

Phase 13

Preclinical5

By Therapeutic Area

top 4

Oncology

744%

Musculoskeletal

16%

Nephrology

16%

Cardiovascular

16%

R&D Momentum

74/100

Pipeline Velocity

43/100

Trial Completion Rate

63/100

Pipeline Concentration

34/100

Pipeline Freshness

63/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 4, 2026

Recruiting

Liposomal Irinotecan (Nal-IRI) Plus 5-fluorouracil and Leucovorin (5-FU/LV) Plus Oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients With Advanced Small Intestine and Appendiceal Cancers

Oct 31, 2026

Recruiting

Dexamethasone for Ureteral STent Symptoms (DUSTS): A Randomized, Double-blinded Controlled Study

Oct 29, 2026

Completed

Phase 2a Study of the Expansion and Infusion of Autologous T-Regulatory Cells in Amyotrophic Lateral Sclerosis

Oct 27, 2026

Recruiting

Augmenting Upper Limb Function and Functional Neuroplasticity Using Epidural Stimulation of the Cervical Spinal Cord

Earlier

Oct 9, 2026TrialAtezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

Oct 9, 2026TrialPhase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Oct 9, 2026TrialEvaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Oct 8, 2026TrialRandomized Phase II Trial of 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

4 more events

Oct 8, 2026TrialPhase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer

Oct 8, 2026TrialNeoadjuvant Combination Therapy of Lenvima Plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients With Large Hepatocellular Carcinoma

Oct 2, 2026TrialSemaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer

Sep 24, 2026TrialA Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

L-NMMAPhase 2

Carcinoma, Non-Small-Cell Lung

HonokiolPhase 1

Colorectal Cancer

Fruquintinib Combined With ChemotherapyPreclinical

Colorectal Carcinoma

HydroxytyrosolPhase 1

Metastatic Colorectal Cancer

Fruquintinib Combined With ChemotherapyPhase 2

Prostate Cancer

BrachytherapyPhase 2

HSV-TkPhase 2

Unknown / Other

Chemotherapy

ADV/HSV-tkPhase 2

Newly Diagnosed

ADV/HSV-tkPhase 2

Pembrolizumab

L-NMMAPhase 1

Total Knee Arthroplasty

IO Administration of CefazolinPhase 2

Showing 15 of 20 programs

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)